Intensive Glucose Lowering and Adverse CV Outcomes in Patients with Type 2 Diabetes

A meta-analysis suggests that intensive therapy beneficially affects rates of adverse coronary events but does not change rates of stroke or all-cause mortality during 10 years.

In the ACCORD, ADVANCE, and VADT trials, intensive glucose-lowering therapy in patients with type 2 diabetes did not lower risk for adverse cardiovascular (CV) events and early mortality (JW Gen Med Jun 6 2008 and JW Gen Med Dec 24 2008). In fact, in the ACCORD trial, intensive treatment was associated with higher mortality. In a new meta-analysis of five randomized trials (including the ACCORD, ADVANCE, and VADT trials) that involved more than 33,000 patients with type 2 diabetes, U.K. investigators sought to clarify the effects of intensive glucose-lowering therapy on mortality and major CV events.

Outcomes assessed were nonfatal myocardial infarction, coronary heart disease events (fatal and nonfatal MI), stroke, and all-cause mortality. …

Reviewing Author

Paul S. Mueller, MD, MPH, FACP

Disclosures

Nothing to disclose

Paul S. Mueller, MD, MPH, FACP

Disclosures

Nothing to disclose

Intensive Glucose Lowering and Adverse CV Outcomes in Patients with Type 2 Diabetes

Topics

Reviewing Author